Why CRISPR Therapeutics Stock Sank 50.5% in 2021 and Continues to Fall
Shares of CRISPR Therapeutics (NASDAQ: CRSP) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.
Source Fool.com